跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 32 条关于
“ARASENS”
全部
32
临床试验
5
药物
1
机构
0
资讯
26
3年前
Darolutamide Demonstrates Efficacy in Chinese Patients with Metastatic Hormone-Sensitive Prostate Cancer
去年
Darolutamide Shows Consistent Benefits Across Age Groups in Metastatic Prostate Cancer ARASENS Trial Analysis
2年前
Darolutamide Improves Survival in Chinese Patients with Metastatic Hormone-Sensitive Prostate Cancer
去年
Triplet Therapy vs. Doublet Therapy in Metastatic Prostate Cancer: A Treatment Debate
去年
NUBEQA Shows Strong Efficacy in Metastatic Prostate Cancer Subgroups, New Trial Data Reveals
3年前
Darolutamide Approved in China for Metastatic Hormone-Sensitive Prostate Cancer
2年前
Darolutamide Shows Promising Results in Treating Metastatic Hormone-Sensitive Prostate Cancer
2年前
NCCN Updates Prostate Cancer Guidelines: Stratified Treatment for Metastatic Hormone-Sensitive Disease
2年前
NUBEQA Plus ADT Demonstrates 46% Risk Reduction in Metastatic Hormone-Sensitive Prostate Cancer
去年
Biomarker-Driven Precision Medicine Transforms Treatment Landscape for Metastatic Castration-Sensitive Prostate Cancer
第 1 页,共 3 页
上一页
下一页